Panacea Biotec zooms on collaborating with Refana for Covid-19 vaccine

11 Jun 2020 Evaluate

Panacea Biotec is currently trading at Rs. 241.95, up by 39.15 points or 19.30% from its previous closing of Rs. 202.80 on the BSE.

The scrip opened at Rs. 229.95 and has touched a high and low of Rs. 243.35 and Rs. 220.20 respectively. So far 241355 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 243.35 on 11-Jun-2020 and a 52 week low of Rs. 90.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 243.35 and Rs. 153.30 respectively. The current market cap of the company is Rs. 1486.86 crore.

The promoters holding in the company stood at 73.59%, while Institutions and Non-Institutions held 1.76% and 24.65% respectively.

Panacea Biotec has collaborated with Refana Inc. USA to make Covid-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company to be based in Ireland. The collaboration aims to bring to patients a whole inactivated virus-based vaccine for Covid-19.

Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World. Both Panacea and Refana will undertake sales and distribution of the vaccine in their respective territories.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

563.65 26.60 (4.95%)
29-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.80
Dr. Reddys Lab 1176.25
Cipla 1541.00
Lupin 2067.40
Zydus Lifesciences 887.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...